ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral presentations, and several poster presentations, will be presented at the American Society of Gene and Cell Therapy's 23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Presentations and posters will be available at www.asgct.org.
The oral presentations include:
Abstract Title: Quantitative PET/CT based pharmacokinetic study of AAV9 administered to the cerebrospinal fluid of non-human primates (abstract #135) Session Title: AAV Vectors Preclinical and Proof-of-Concept Studies in Optimizing the ToolboxPresenter: Mikhail Papisov, Ph.D., Massachusetts General Hospital, Shriners Hospitals for Children, Harvard Medical SchoolDate/Time: Tuesday, May 12, 2020 from 4:00 - 4:15 p.m. ET
Abstract Title: RGX-314 Ocular Gene Therapy: Overview of Phase I/IIa Ongoing Trial for Neovascular Age-related Macular Degeneration (nAMD) and Future Directions (abstract #1305)Session Title: AAV Vectors - Clinical StudiesPresenter: Olivier Danos, Ph.D., Senior Vice President and Chief Scientific Officer, REGENXBIO Date/Time: Friday, May 15, 2020 from 10:15-10:30 a.m. ET
Abstract Title: AAV gene therapy in mucopolysaccharidosis IVA murine models (abstract #1351)Session Title: Gene Therapy for Inborn Errors of Metabolism: New ApproachesPresenter: Shunji Tomatsu, M.D., Ph.D., Nemours/Alfred I. duPont Hospital for ChildrenDate/Time: Friday, May 15, 2020 from 11:15-11:30 a.m. ET
The posters include:
Abstract Title: AAV-mediated antibody delivery for hereditary angioedema (abstract #190)Presenter: Joseph T. Bruder, Ph.D., Senior Director, Target Discovery, REGENXBIOSession Title: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/Time: Tuesday, May 12, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Interim data from the first in human RGX-121 gene therapy trial for the treatment of severe MPS II (Hunter syndrome) (abstract #614) Presenter: Marie-Laure Nevoret, M.D., Senior Clinical Development Lead, REGENXBIOSession Title: AAV Vectors - Clinical StudiesDate/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Development of a vectorized antibody platform for liver and skeletal muscle gene transfer (abstract #556) Presenter: Devin S. McDougald, Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIOSession Title: AAV Vectors – Virology & Vectorology Date/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Use of Prophylactic Steroids to Mitigate Potential T-Cell Response in AAV8-Mediated hLDLR Gene Transfer in Subjects with Homozygous Familial Hypercholesterolemia (abstract #612) Presenter: Marina Cuchel, M.D., Ph.D., University of PennsylvaniaSession Title: AAV Vectors - Clinical StudiesDate/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Process development and scaleup comparisons for transient Production of AAV (abstract #1266)Presenter: Robert Stadelman, Senior Scientist, REGENXBIOSession Title: Vector and Cell Engineering, Production or ManufacturingDate/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Structural and biochemical characterization of potentially under-utilized gene therapy vector AAV7 (abstract #1007) Presenter: Samantha A. Yost, Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIOSession Title: AAV Vectors - Virology and VectorologyDate/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Development of a Sensitive and Robust Cell-Based Assay for Measuring Potency of the NAV AAV8 Vector-Derived RGX-314 Gene Therapy Product for the Treatment of Wet Age-Related Macular Degeneration (abstract #1005) Presenter: Raza Zaidi, Senior Associate Scientist, REGENXBIOSession Title: AAV Vectors - Virology and VectorologyDate/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
About REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:Tricia TruehartInvestor Relations and Corporate Communications347-926-7709ttruehart@regenxbio.com
Investors:Heather Savelle, 212-600-1902heather@argotpartners.com
Media:David Rosen, 212-600-1902david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapys-23rd-annual-meeting-301048853.html
SOURCE REGENXBIO Inc.